Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T1GF
|
|||
| Former ID |
DCL000171
|
|||
| Drug Name |
MP470
|
|||
| Synonyms |
Amuvatinib; 850879-09-3; MP-470; MP470; MP 470; Amuvatinib (MP-470); HPK56; UNII-SO9S6QZB4R; Amuvatinib(MP470); N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; SO9S6QZB4R; HPK-56; HPK 56; N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro-[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; Amuvatinib [USAN:INN]; Amuvatinib (MP-470, HPK 56); PubChem22479; Amuvatinib (USAN/INN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1], [2], [3] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
SuperGen
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H21N5O3S
|
|||
| Canonical SMILES |
C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6
|
|||
| InChI |
1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)
|
|||
| InChIKey |
FOFDIMHVKGYHRU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 850879-09-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16369229, 23453848, 42361725, 77946799, 99437047, 124757111, 125163915, 131480736, 134338846, 135263011, 135626621, 135685152, 135685153, 135685172, 136340107, 136367369, 136367870, 137275712, 137276002, 139988781, 143499562, 144116253, 152234887, 152258122, 160646961, 160708511, 162011866, 162037515, 162202665, 163782381, 164194061, 165247706, 174561001, 177748917, 186022477, 188899560, 198969243, 223387929, 223705031, 223972211, 226471652, 242059854, 243943799, 249565615, 252160959, 252215845, 252543326, 252671616
|
|||
| ChEBI ID |
CHEBI:91389
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7932). | |||
| REF 2 | Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. | |||
| REF 3 | The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol. 2011 Oct;101(1):59-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.